research Cutaneous signals of immune system disease
Skin issues can indicate immune system problems.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
research Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin
Stress increases nerve fibers and immune cell activity in mouse skin, possibly worsening skin conditions.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research The impact of SARS-CoV-2 and COVID-19 on male reproduction and men’s health
COVID-19 might affect male fertility, but more research is needed to understand the full impact.
research The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Immune cell regulation of the hair cycle
Immune cells affect hair growth and could lead to new hair loss treatments.
research Group IID, IIE, IIF and III secreted phospholipase A2s
Different sPLA2 enzymes affect immunity, skin and hair health, reproduction, and may be potential targets for therapy.
research Cutaneous manifestations associated with immune checkpoint inhibitors
Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Differential effects of Wnt5a on the proliferation, differentiation and inflammatory response of keratinocytes
Wnt5a may contribute to psoriasis by reducing skin cell growth, blocking skin cell maturation, and increasing inflammation.
research Alopecia Universalis Following Two Sequential Traffic Accidents : Possible Association with Increased Th1 and Th17 Cells and Decreased Th2 Cells
Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.
research NF-κB in biology and targeted therapy: new insights and translational implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.
research Increased Incidence of Telogen Effluvium Following Platelet-Rich Plasma Therapy in Patients with Elevated TNF-α Expression: A Prospective Cohort Study
High TNF-α levels may increase hair loss risk after PRP therapy.
research Exploring the role of two polypeptide nanofiber gels derived from RADA16-I self-assembly in accelerating burn wound healing
RG and RJ gels speed up burn wound healing better than other treatments.
research Malasseziai> and the Asian menopausal skin
Menopause-related skin changes may increase fungal infections and inflammation.
research Immunoglobulin E and Serum Interleukin-13 and Bacteria in Patients with Alopecia Areata
Alopecia areata patients have higher IgE and IL-13 levels, suggesting immune involvement.
research Comparative investigation of immune-related biomarkers related to alopecia areata subtypes
Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research THE PATTERN AND CLINICAL PROFILE OF ALOPECIA AREATA. PANORAMIC REVIEW: UPDATE AND ADVANCES ON ETIOPATHOGENESIS, ASSOCIATED FACTORS, DIAGNOSIS, COMPLICATIONS, MANAGEMENT AND PROGNOSIS IN TREATMENT 2023
Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.
research T cell and bacterial microbiota interaction at intestinal and skin epithelial interfaces
T cells and bacteria in the gut and skin help maintain health and protect against disease.
research Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
Stress-related hair loss was reversed with a special medication.
research 1378 Identification of two distinct stem cell clusters, Lrig1-derived and Wnt/CD44-dependent, in corneal epithelium
The conclusion is that the cornea has two types of stem cells, with Lrig1+ cells being key for renewal in aging corneas, independent of CD44.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Effect of immunosuppressive ppiase inhibitors, cyclosporin A, FK506, ascomycin and rapamycin on hair growth initiation
Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.
research Interrelation of immunity and tissue repair or regeneration
The immune system plays a key role in tissue repair, affecting both healing quality and regenerative ability.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.